Owkin — an AI company focused on unraveling the complexity of biology and advancing new diagnostics and therapies — partnered with STAT Brand Studio on a Pulse Check report to survey more than 200 executives and researchers in the U.S. and Europe about agentic AI.
The report examines how leaders perceive this emerging technology, from its potential to streamline discovery and research to the strategic priorities, adoption strategies, budgets, and barriers that shape its role in biopharma.
Sponsored by 
Produced by 
Commissioned by Owkin and STAT Brand Studio, this Pulse Check captures the perspectives of more than 200 pharma executives and researchers in the U.S. and Europe on the role of agentic AI in their work. Unlike traditional AI, agentic AI can proactively plan, act, and adapt — a capability with far-reaching implications for drug discovery, clinical trials, and data management. The report examines how industry leaders and technical teams are evaluating its potential, the strategies they favor for implementation, and the barriers that shape adoption. It provides a data-driven perspective on how the next wave of AI might transform the biopharmaceutical pipeline.
Owkin is an AI company on a mission to unravel the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biology-specific large language models, multimodal patient data, and agentic software. At the core of this system is Owkin K, an agentic copilot, and Owkin Zero, a new LLM fine-tuned on biology. Together, they are used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and accelerate the development of diagnostics and therapies.